FASTKD2

FAST kinase domain-containing protein 2 (FASTKD2) is a protein that in humans is encoded by the FASTKD2 gene on chromosome 2.[5][6] This protein is part of the FASTKD family, which is known for regulating the energy balance of mitochondria under stress. FASTKD2 has been implicated in mitochondrial encephalomyopathy, breast cancer, and prostate cancer.[7][8][9]

FASTKD2
Identifiers
AliasesFASTKD2, KIAA0971, FAST kinase domains 2, COXPD44
External IDsOMIM: 612322 MGI: 1922869 HomoloGene: 8957 GeneCards: FASTKD2
Gene location (Human)
Chr.Chromosome 2 (human)[1]
Band2q33.3Start206,765,357 bp[1]
End206,796,189 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

22868

75619

Ensembl

ENSG00000118246

ENSMUSG00000025962

UniProt

Q9NYY8

Q922E6

RefSeq (mRNA)

NM_014929
NM_001136193
NM_001136194

NM_172422

RefSeq (protein)

NP_001129665
NP_001129666
NP_055744

NP_766010

Location (UCSC)Chr 2: 206.77 – 206.8 MbChr 1: 63.73 – 63.75 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Structure

FASTKD2 shares structural characteristics of the FASTKD family, including a ~50-amino acid N-terminal mitochondrial targeting domain and three C-terminal domains: two FAST kinase-like domains (FAST_1 and FAST_2) and a RNA-binding domain (RAP).[7][8] The mitochondrial targeting domain directs FASTKD2 to be imported into the mitochondria. Though the functions of the C-terminal domains are unknown, RAP possibly binds RNA during trans-splicing.[7]

Function

As a member of the FASTKD family, FASTKD2 localizes to the inner mitochondrial membrane to modulate their energy balance, especially under conditions of stress.[7][8] Though ubiquitously expressed in all tissues, FASTKD2 appears more abundantly in skeletal muscle, heart muscle, and other tissues enriched in mitochondria.[7] Nonetheless, FASTKD2 has been observed to mediate apoptosis independent of import into the mitochondria, suggesting that it interacts with proteins on the outer mitochondrial membrane. This protein possibly contributes its proapoptotic function through a caspase-dependent pathway, by activating proapoptotic factors or inhibiting antiapoptotic factors, but the exact mechanism remain unclear.[8][9] FASTKD2 has also been validated as an RNA-binding protein.[10][11]

Clinical significance

FASTKD2 is an important apoptotic constituent. During a normal embryologic processes, or during cell injury (such as ischemia-reperfusion injury during heart attacks and strokes) or during developments and processes in cancer, an apoptotic cell undergoes structural changes including cell shrinkage, plasma membrane blebbing, nuclear condensation, and fragmentation of the DNA and nucleus. This is followed by fragmentation into apoptotic bodies that are quickly removed by phagocytes, thereby preventing an inflammatory response.[12] It is a mode of cell death defined by characteristic morphological, biochemical and molecular changes. It was first described as a "shrinkage necrosis", and then this term was replaced by apoptosis to emphasize its role opposite mitosis in tissue kinetics. In later stages of apoptosis the entire cell becomes fragmented, forming a number of plasma membrane-bounded apoptotic bodies which contain nuclear and or cytoplasmic elements. The ultrastructural appearance of necrosis is quite different, the main features being mitochondrial swelling, plasma membrane breakdown and cellular disintegration. Apoptosis occurs in many physiological and pathological processes. It plays an important role during embryonal development as programmed cell death and accompanies a variety of normal involutional processes in which it serves as a mechanism to remove "unwanted" cells.

FASTKD2 has been linked to mitochondrial encephalomyopathy associated with cytochrome c oxidase deficiency (mitochondrial complex IV deficiency). Nonsense mutations in FASTKD2 produce a truncated protein that cuts off the RAP domain and part of the FAST domains, leading to dampened sensitivity to apoptotic stimuli.[7][10] Moreover, breast cancer cells are protected against apoptosis by stimulating NRIF3/DD1 expression or DIF-1 knockdown, which thus suppresses the proapoptotic function of FASTKD2.[8] The proapoptotic function is similarly observed in prostate cancer cells, but not in other cells; it is suggested that susceptibility to FASTKD2-mediated apoptosis requires certain factors to associate with the DIF-1 complex to bind.[9] Thus far, activating and enhancing expression of FASTKD2 may prove effective in killing breast and prostate cancer cells.[8][9]

Interactions

FASTKD2 has been shown to interact with FASTKD3.[7] The FASTKD2 gene has been observed to bind the DIF-1 complex.[8]

References
  1. GRCh38: Ensembl release 89: ENSG00000118246 - Ensembl, May 2017
  2. GRCm38: Ensembl release 89: ENSMUSG00000025962 - Ensembl, May 2017
  3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. UniProt: Q9NYY8
  6. "Entrez Gene: FAST kinase domains 2".
  7. Simarro M, Gimenez-Cassina A, Kedersha N, Lazaro JB, Adelmant GO, Marto JA, Rhee K, Tisdale S, Danial N, Benarafa C, Orduña A, Anderson P (October 2010). "Fast kinase domain-containing protein 3 is a mitochondrial protein essential for cellular respiration". Biochemical and Biophysical Research Communications. 401 (3): 440–6. doi:10.1016/j.bbrc.2010.09.075. PMC 2963690. PMID 20869947.
  8. Yeung KT, Das S, Zhang J, Lomniczi A, Ojeda SR, Xu CF, Neubert TA, Samuels HH (June 2011). "A novel transcription complex that selectively modulates apoptosis of breast cancer cells through regulation of FASTKD2". Molecular and Cellular Biology. 31 (11): 2287–98. doi:10.1128/MCB.01381-10. PMC 3133243. PMID 21444724.
  9. Das S, Yeung KT, Mahajan MA, Samuels HH (November 2014). "Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain". BMC Cancer. 14: 852. doi:10.1186/1471-2407-14-852. PMC 4256816. PMID 25409762.
  10. Castello A, Fischer B, Eichelbaum K, Horos R, Beckmann BM, Strein C, Davey NE, Humphreys DT, Preiss T, Steinmetz LM, Krijgsveld J, Hentze MW (June 2012). "Insights into RNA biology from an atlas of mammalian mRNA-binding proteins". Cell. 149 (6): 1393–406. doi:10.1016/j.cell.2012.04.031. PMID 22658674.
  11. Baltz AG, Munschauer M, Schwanhäusser B, Vasile A, Murakawa Y, Schueler M, Youngs N, Penfold-Brown D, Drew K, Milek M, Wyler E, Bonneau R, Selbach M, Dieterich C, Landthaler M (June 2012). "The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts". Molecular Cell. 46 (5): 674–90. doi:10.1016/j.molcel.2012.05.021. PMID 22681889.
  12. Kerr JF, Wyllie AH, Currie AR (August 1972). "Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics". British Journal of Cancer. 26 (4): 239–57. doi:10.1038/bjc.1972.33. PMC 2008650. PMID 4561027.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.